HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Making lifestyle changes ‘part of the cancer treatment conversation’
-
- ‘Precision nutrition’ may be on the horizon, but large-scale, definitive trials lacking Lindsay L. Peterson, MD, MSCR
- American Society for Radiation Oncology announces president-elect, new board members
- The unspoken truth about financial toxicity John Sweetenham, MD, FRCP, FACP
- APPs can serve as ‘advocate, coordinator’ for patients with chronic GVHD Linda M. Perry, MS, PA-C
- Risk, phenotypes, therapeutics and resistance Wafik S. El-Deiry, MD, PhD, FACP
- Study to evaluate breast cancer screening approaches amid mammography guidelines debate
- Expense reimbursement model aims to ‘level playing field’ for clinical trial participation
- Factors may help predict which patients with HER2-positive breast cancer can forgo surgery
-
- Anticoagulants may reduce VTE risk in children
- FDA-approved cancer drugs take more than 6 years to reach children
- Direct oral anticoagulants safe, effective in patients with VTE and thrombophilia
- Alpelisib plus fulvestrant extends PFS in PIK3CA-mutated advanced breast cancer
- Colorectal cancer subtypes could help predict best initial treatment option
- Gene expression patterns identify high-risk chronic lymphocytic leukemia
- Osimertinib shows 'consistent improvement' in post-progression endpoints for non-small cell lung cancer
- Persistent HPV DNA may predict progression of certain head and neck cancers
-
- Pembrolizumab approved for two solid tumor indications
- FDA approves Zirabev, biosimilar to Avastin
- Leukemia Research Foundation awards grants to 12 investigators